Cognex Articles
Enrollment continues in Voyager's Ph III AD trial
24 April 2006
Novartis gains US approval for Exelon
25 April 2000
1997: Another Good Year For New Chemical Entities
6 January 1998
1st Launches For Novartis' Exelon And CoDiovan
21 November 1997
Focus On Exelon For Alzheimer's Disease
14 August 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
W-L To Phase-Out Cognex Marketing
19 June 1997
Eisai Launches Aricept In The UK, Its Second Market
8 April 1997
Novartis To File Exelon Worldwide This Month
20 March 1997
Aricept Approved In Second Market
3 March 1997
Eisai's Aricept Available In USA, Its First Market
27 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
First Approval Of Eisai's Aricept For Alzheimer's
2 December 1996
Sandoz' Alzheimer's Drug; International Data Revealed
2 December 1996
Galanthamine Enters Ph III In USA For Alzheimer's
28 October 1996
Pfizer Drops Tenidap For RA, But OA Still An Option
7 October 1996
First Efficacy Data With Sandoz' Exelon
5 August 1996
Shire's Alzheimer's Drug Shows Promise
5 August 1996
Takeda's Idebenone Filed In Germany
5 August 1996
Shire: An Emerging Firm With A Difference
20 May 1996
Eisai Files For Aricept In USA; Phase III Data
8 April 1996
Bayer Details Near-Term Product Expectations
1 April 1996
European Alzheimer's/ Dementia markets
11 March 1996
Shire Signs Alzheimer's Drug Rights To Janssen
29 January 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Astra Strengthens R&D With Increased Spending
4 December 1995
Warner-Lambert: Cognex cash for research
14 August 1995
Chinoin's Selegiline For Alzheimer's?
17 July 1995
Bayer's First Pipeline Presentation: Part 1
19 June 1995
Dopamine Hypothesis For AAMI?
22 May 1995
Atorvastatin Superior To Other Statins?
24 April 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
CSM Clamps Down On Cyproterone Acetate..
27 March 1995
Cognex Approved In Sweden
6 March 1995
L10 Million Interim Funding For Shire Pharma
6 March 1995
New Approach To Alzheimer's?
20 February 1995
Pfizer, Eisai To Codevelop Alzheimer's Drugs
5 December 1994
Cognitive Enhancers Unveiled At ASM
21 November 1994
Cognex Launch In France
24 October 1994
Cognex Prescribing Slower Than Expected
17 October 1994
Cognex Results In Longer-Term Therapy
10 October 1994
Hoechst's Propentofylline Set For Spring '95 Filing
3 October 1994
Hoechst-Roussel Drops Velnacrine
15 August 1994
SIZING UP THE MARKET FOR GERIATRIC MEDICINE
20 June 1994
COGNEX APPROVED IN FRANCE
16 May 1994
CNS DISORDERS IN THE COMING DECADE
16 May 1994
WARNER-LAMBERT POSTS 1st QTR GROWTH
25 April 1994
MIXED RESULTS WITH HIGH DOSE TACRINE
11 April 1994
LIGHT AT THE END OF THE TUNNEL FOR HOECHST?
28 March 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
ANTI-HIV, ALZHEIMER'S MARKET FORECASTS
20 December 1993
NIKKEN PROGRESS ON DEMENTIA DRUG
20 December 1993
WORLD MARKETS FOR CNS AND GASTROINTESTINALS
13 December 1993
NEW YORK STOCK COMMENT
29 November 1993
COGNEX SALES "ON TARGET"
15 November 1993
HOECHST-ROUSSEL TO FIGHT COGNEX PATENT
11 October 1993
HMO EXCLUDES COGNEX FROM FORMULARY
4 October 1993
COGNEX APPROVED FOR ALZHEIMER'S IN USA
20 September 1993
WARNER-LAMBERT CONSENT AGREEMENT
23 August 1993
SKIN TEST FOR ALZHEIMER'S
16 August 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
COGNEX APPROVAL "IMMINENT"
19 July 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
WARNER-LAMBERT LICENSING DEAL
31 May 1993
COGNEX LABELLING RULING
10 May 1993
ALL HOPES ON COGNEX AT WARNER-LAMBERT
26 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
WARNER-LAMBERT A "SWEET SPOT IN A SOUR MARKET"
19 April 1993
NEW YORK STOCK COMMENT
5 April 1993
TACRINE CLEARS APPROVAL HURDLE
29 March 1993
HOECHST DISSATISFIED WITH 1992 RESULTS
29 March 1993
CURRENT CONCEPTS IN ALZHEIMER'S DISEASE
22 March 1993
COGNEX SET FOR THIRD APPRAISAL
8 March 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
JOUVEINAL PRODUCTS EFFECT ON W-L PIPELINE
8 February 1993
DAIICHI'S DEMENTIA DRUG: FILING IN 1993?
4 January 1993
ICI AT "BREAKING POINT" WITH DEMERGER
14 December 1992
FOREST LABS' SYNAPTON TRIALS
7 December 1992
HOECHST ALZHEIMER DRUG REJECTED
9 November 1992
NEW INFORMATION ON ALZHEIMER'S DISEASE
2 November 1992
TACRINE USE IN USA
5 October 1992
COGNEX TRIAL RESULTS
3 August 1992
Warner Lambert study
29 June 1992
WARNER-LAMBERT'S VIEW TO THE FUTURE
27 April 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
OPTIMISTIC ANALYSIS OF WARNER-LAMBERT
13 April 1992
STOCK MARKET COMMENTARY: NEW YORK
9 March 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
ALZHEIMER'S DISEASE: A GROWING BURDEN
20 January 1992
TEATMENT IND FOR W-L'S COGNEX
6 January 1992
Showing 1-98 of 98 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
